IFIH1 and clinically amyopathic dermatomyositis: The production of anti-MDA5 antibodies is strongly associated with DM, especially with CADM, and rapidly progressive ILD (RP-ILD), and this subset is associated with particularly poor clinical outcomes [3–11].